At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
AZD8683, 50 mcg +2 moredrug
Likely dose
AZD8683, 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled, Randomised, Multi-centre, 3-way Cross-over, Single-dose Phase II Study to Investigate the Local and Systemic Effects of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating AZD8683, 50 mcg, Placebo, and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 28 participants across 4 sites.
Detailed Summary
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedSep 20, 2010
Enrollment StartOct 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.8 years ago
Interventions
AZD8683, 50 mcgdrug
Dry powder for inhalation, single dose
Placebodrug
Dry powder for inhalation, single dose
AZD8683, 200 mcgdrug
Dry powder for inhalation, single dose